| 17alpha-ethynylestradiol | affects expression | ISO | RGD:734269 | 6480464 | Ethinyl Estradiol affects the expression of ANXA5 mRNA | CTD | PMID:17555576 |
| 17alpha-ethynylestradiol | increases expression | ISO | RGD:2120 | 6480464 | Ethinyl Estradiol results in increased expression of ANXA5 mRNA | CTD | PMID:12655037 |
| 2,2,2-tetramine | multiple interactions | ISO | RGD:2120 | 6480464 | Trientine inhibits the reaction [Streptozocin results in decreased expression of ANXA5 protein] | CTD | PMID:19634143 |
| 2,2,2-tetramine | multiple interactions | ISO | RGD:2120 | 6480464 | Trientine inhibits the reaction [Streptozocin results in increased expression of ANXA5 protein] | CTD | PMID:21136691 |
| 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:734269 | 6480464 | Tetrachlorodibenzodioxin affects the expression of ANXA5 mRNA | CTD | PMID:21570461 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:2120 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of ANXA5 mRNA | CTD | PMID:20959002 |
| 3,3',4,4',5-pentachlorobiphenyl | increases expression | ISO | RGD:2120 | 6480464 | 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of ANXA5 mRNA | CTD | PMID:20959002 |
| 3H-1,2-dithiole-3-thione | decreases expression | ISO | RGD:2120 | 6480464 | 1,2-dithiol-3-thione results in decreased expression of ANXA5 mRNA | CTD | PMID:19162173 |
| 4,4'-diaminodiphenylmethane | decreases expression | ISO | RGD:2120 | 6480464 | 4,4'-diaminodiphenylmethane results in decreased expression of ANXA5 mRNA | CTD | PMID:18289764 |
| 5-aza-2'-deoxycytidine | multiple interactions | EXP | | 6480464 | [decitabine co-treated with vorinostat] affects the expression of ANXA5 mRNA | CTD | PMID:17330099 |
| 5-aza-2'-deoxycytidine | increases expression | EXP | | 6480464 | decitabine results in increased expression of ANXA5 mRNA | CTD | PMID:16367923 |
| acrylamide | increases expression | EXP | | 6480464 | Acrylamide results in increased expression of ANXA5 protein | CTD | PMID:22543296 |
| aflatoxin B1 | increases expression | ISO | RGD:734269 | 6480464 | Aflatoxin B1 results in increased expression of ANXA5 mRNA | CTD | PMID:19770486 |
| all-trans-retinoic acid | increases expression | EXP | | 6480464 | Tretinoin results in increased expression of ANXA5 mRNA | CTD | PMID:15982314 |
| all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of ANXA5 mRNA | CTD | PMID:21934132 |
| all-trans-retinoic acid | increases expression | ISO | RGD:734269 | 6480464 | Tretinoin results in increased expression of ANXA5 mRNA | CTD | PMID:16604517 |
| ammonium chloride | affects expression | ISO | RGD:2120 | 6480464 | Ammonium Chloride affects the expression of ANXA5 mRNA | CTD | PMID:16483693 |
| asbestos | increases expression | EXP | | 6480464 | Asbestos results in increased expression of ANXA5 mRNA | CTD | PMID:22398240 |
| bacitracin | increases expression | ISO | RGD:2120 | 6480464 | Bacitracin results in increased expression of ANXA5 mRNA | CTD | PMID:18289764 |
| benzo[a]pyrene | increases expression | ISO | RGD:2120 | 6480464 | Benzo(a)pyrene results in increased expression of ANXA5 mRNA | CTD | PMID:21839799 |
| benzo[a]pyrene | increases expression | EXP | | 6480464 | Benzo(a)pyrene results in increased expression of ANXA5 protein | CTD | PMID:22581694 |
| beryllium sulfate | increases expression | EXP | | 6480464 | beryllium sulfate results in increased expression of ANXA5 mRNA | CTD | PMID:16314022 |
| calcium atom | multiple interactions | EXP | | 6480464 | Calcium promotes the reaction [Phosphatidylserines binds to ANXA5 protein] | CTD | PMID:16076491 |
| calcium atom | multiple interactions | EXP | | 6480464 | Calcium binds to and results in increased activity of ANXA5 protein | CTD | PMID:11578147 |
| calcium(0) | multiple interactions | EXP | | 6480464 | Calcium promotes the reaction [Phosphatidylserines binds to ANXA5 protein] | CTD | PMID:16076491 |
| calcium(0) | multiple interactions | EXP | | 6480464 | Calcium binds to and results in increased activity of ANXA5 protein | CTD | PMID:11578147 |
| choline | multiple interactions | ISO | RGD:734269 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of ANXA5 mRNA | CTD | PMID:20938992 |
| cisplatin | decreases expression | EXP | | 6480464 | Cisplatin results in decreased expression of ANXA5 protein | CTD | PMID:21924258 |
| cisplatin | increases expression | ISO | RGD:2120 | 6480464 | Cisplatin results in increased expression of ANXA5 mRNA | CTD | PMID:18289764 |
| clofibrate | multiple interactions | ISO | RGD:734269 | 6480464 | [Clofibrate co-treated with Acetaminophen] affects the expression of ANXA5 mRNA; more ... | CTD | PMID:17585979 |
| cobalt atom | increases expression | ISO | RGD:734269 | 6480464 | Cobalt results in increased expression of ANXA5 mRNA | CTD | PMID:22147119 |
| copper atom | affects binding | EXP | | 6480464 | ANXA5 protein binds to Copper | CTD | PMID:15359738 |
| copper atom | multiple interactions | EXP | | 6480464 | [MT1 protein co-treated with MT2 protein] affects the reaction [Copper results in increased expression of ANXA5 mRNA] | CTD | PMID:16629173 |
| copper(0) | affects binding | EXP | | 6480464 | ANXA5 protein binds to Copper | CTD | PMID:15359738 |
| copper(0) | multiple interactions | EXP | | 6480464 | [MT1 protein co-treated with MT2 protein] affects the reaction [Copper results in increased expression of ANXA5 mRNA] | CTD | PMID:16629173 |
| copper(2+) sulfate | increases expression | EXP | | 6480464 | Copper Sulfate results in increased expression of ANXA5 mRNA | CTD | PMID:19549813 |
| cyclosporin A | increases expression | EXP | | 6480464 | Cyclosporine results in increased expression of ANXA5 mRNA | CTD | PMID:20106945 |
| Delta(9)-tetrahydrocannabinol | decreases expression | EXP | | 6480464 | Tetrahydrocannabinol results in decreased expression of ANXA5 mRNA | CTD | PMID:16039398 |
| dibutyl phthalate | increases expression | ISO | RGD:734269 | 6480464 | Dibutyl Phthalate results in increased expression of ANXA5 mRNA | CTD | PMID:21266533 |
| dibutyl phthalate | decreases expression | ISO | RGD:2120 | 6480464 | Dibutyl Phthalate results in decreased expression of ANXA5 mRNA | CTD | PMID:17379624 |
| dibutyl phthalate | increases expression | ISO | RGD:734269 | 6480464 | Dibutyl Phthalate results in increased expression of ANXA5 mRNA | CTD | PMID:17361019 PMID:21266533 |
| dibutyl phthalate | increases expression | ISO | RGD:2120 | 6480464 | Dibutyl Phthalate results in increased expression of ANXA5 mRNA | CTD | PMID:21266533 |
| dichlorine | multiple interactions | ISO | RGD:2120 | 6480464 | [Ozone co-treated with Chlorine] results in decreased expression of ANXA5 mRNA | CTD | PMID:18636392 |
| doxorubicin | multiple interactions | ISO | RGD:2120 | 6480464 | THPO protein inhibits the reaction [Doxorubicin results in increased expression of ANXA5 protein] | CTD | PMID:16651473 |
| doxorubicin | increases expression | ISO | RGD:2120 | 6480464 | Doxorubicin results in increased expression of ANXA5 protein | CTD | PMID:16651473 |
| fluoxetine | multiple interactions | EXP | | 6480464 | Fluoxetine promotes the reaction [Phosphatidylserines binds to ANXA5 protein] | CTD | PMID:16076491 |
| fluoxetine | affects expression | ISO | RGD:2120 | 6480464 | Fluoxetine affects the expression of ANXA5 mRNA | CTD | PMID:21852994 |
| folic acid | multiple interactions | ISO | RGD:734269 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of ANXA5 mRNA | CTD | PMID:20938992 |
| fumonisin B1 | increases expression | ISO | RGD:734269 | 6480464 | fumonisin B1 results in increased expression of ANXA5 mRNA | CTD | PMID:16221962 |
| furan | increases expression | ISO | RGD:2120 | 6480464 | furan results in increased expression of ANXA5 mRNA | CTD | PMID:15120968 |
| genistein | increases expression | ISO | RGD:2120 | 6480464 | Genistein results in increased expression of ANXA5 mRNA | CTD | PMID:21782745 |
| graphite | increases expression | EXP | | 6480464 | Graphite results in increased expression of ANXA5 protein | CTD | PMID:22157353 |
| griseofulvin | increases expression | ISO | RGD:734269 | 6480464 | Griseofulvin results in increased expression of ANXA5 mRNA | CTD | PMID:12735108 |
| hyaluronic acid | decreases expression | ISO | RGD:2120 | 6480464 | Hyaluronic Acid analog results in decreased expression of ANXA5 protein | CTD | PMID:23178681 |
| hyaluronic acid | multiple interactions | ISO | RGD:2120 | 6480464 | Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ANXA5 protein] | CTD | PMID:23178681 |
| hydrazine | increases expression | ISO | RGD:734269 | 6480464 | hydrazine results in increased expression of ANXA5 mRNA | CTD | PMID:15282401 |
| hydrogen peroxide | decreases expression | ISO | RGD:2120 | 6480464 | Hydrogen Peroxide results in decreased expression of ANXA5 protein | CTD | PMID:23178681 |
| hydrogen peroxide | multiple interactions | ISO | RGD:2120 | 6480464 | Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ANXA5 protein] | CTD | PMID:23178681 |
| indole-3-methanol | affects expression | ISO | RGD:2120 | 6480464 | indole-3-carbinol affects the expression of ANXA5 mRNA | CTD | PMID:21396975 |
| indomethacin | increases expression | EXP | | 6480464 | Indomethacin results in increased expression of ANXA5 protein | CTD | PMID:18678619 |
| ketamine | decreases expression | ISO | RGD:2120 | 6480464 | Ketamine results in decreased expression of ANXA5 mRNA | CTD | PMID:20080153 |
| kojic acid | multiple interactions | ISO | RGD:734269 | 6480464 | [Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ANXA5 mRNA | CTD | PMID:17917374 |
| L-ascorbic acid | multiple interactions | ISO | RGD:734269 | 6480464 | [Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ANXA5 mRNA | CTD | PMID:17917374 |
| L-ascorbic acid | increases expression | ISO | RGD:2120 | 6480464 | Ascorbic Acid results in increased expression of ANXA5 mRNA | CTD | PMID:15372504 |
| L-ascorbic acid | increases expression | ISO | RGD:734269 | 6480464 | Ascorbic Acid results in increased expression of ANXA5 protein | CTD | PMID:19224539 |
| L-methionine | multiple interactions | ISO | RGD:734269 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of ANXA5 mRNA | CTD | PMID:20938992 |
| lead diacetate | increases expression | ISO | RGD:2120 | 6480464 | lead acetate results in increased expression of ANXA5 mRNA; more ... | CTD | PMID:11578147 |
| lead diacetate | multiple interactions | EXP | | 6480464 | lead acetate binds to and results in increased activity of ANXA5 protein | CTD | PMID:11578147 |
| lithium atom | increases expression | ISO | RGD:2120 | 6480464 | Lithium results in increased expression of ANXA5 protein | CTD | PMID:18296634 |
| lithocholic acid | increases expression | ISO | RGD:734269 | 6480464 | Lithocholic Acid results in increased expression of ANXA5 mRNA | CTD | PMID:20359477 |
| lithocholic acid | multiple interactions | ISO | RGD:734269 | 6480464 | Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid results in increased expression of ANXA5 mRNA] | CTD | PMID:20359477 |
| lovastatin | decreases expression | ISO | RGD:734269 | 6480464 | Lovastatin results in decreased expression of ANXA5 mRNA | CTD | PMID:20493250 |
| microcystin-LR | increases expression | ISO | RGD:734269 | 6480464 | cyanoginosin LR results in increased expression of ANXA5 mRNA | CTD | PMID:17654400 |
| monocrotaline | multiple interactions | ISO | RGD:734269 | 6480464 | [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of ANXA5 mRNA | CTD | PMID:21224054 |
| N-methyl-N'-nitro-N-nitrosoguanidine | multiple interactions | ISO | RGD:734269 | 6480464 | [Methylnitronitrosoguanidine co-treated with Okadaic Acid] results in increased expression of ANXA5 mRNA | CTD | PMID:19840844 |
| N-nitrosodiethylamine | multiple interactions | ISO | RGD:734269 | 6480464 | [Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ANXA5 mRNA | CTD | PMID:17917374 |
| N-nitrosodiethylamine | increases expression | ISO | RGD:2120 | 6480464 | Diethylnitrosamine results in increased expression of ANXA5 protein | CTD | PMID:20935162 |
| N-nitrosodiethylamine | increases expression | ISO | RGD:2120 | 6480464 | Diethylnitrosamine results in increased expression of ANXA5 mRNA | CTD | PMID:19638242 |
| N-nitrosodiethylamine | multiple interactions | ISO | RGD:2120 | 6480464 | [Diethylnitrosamine co-treated with Phenobarbital] results in increased expression of ANXA5 protein | CTD | PMID:20935162 |
| N-nitrosodiethylamine | multiple interactions | ISO | RGD:2120 | 6480464 | [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of ANXA5 mRNA | CTD | PMID:18164116 |
| N-nitrosodiethylamine | increases expression | ISO | RGD:2120 | 6480464 | Diethylnitrosamine results in increased expression of ANXA5 mRNA | CTD | PMID:12807726 |
| naphthalene | decreases reduction | ISO | RGD:734269 | 6480464 | naphthalene results in decreased reduction of ANXA5 protein | CTD | PMID:19843705 |
| nitric oxide | increases expression | EXP | | 6480464 | Nitric Oxide results in increased expression of ANXA5 protein | CTD | PMID:16024610 |
| okadaic acid | multiple interactions | ISO | RGD:734269 | 6480464 | [Methylnitronitrosoguanidine co-treated with Okadaic Acid] results in increased expression of ANXA5 mRNA | CTD | PMID:19840844 |
| ozone | multiple interactions | ISO | RGD:2120 | 6480464 | [Ozone co-treated with Chlorine] results in decreased expression of ANXA5 mRNA | CTD | PMID:18636392 |
| paracetamol | multiple interactions | ISO | RGD:734269 | 6480464 | [Clofibrate co-treated with Acetaminophen] affects the expression of ANXA5 mRNA; more ... | CTD | PMID:17585979 |
| paracetamol | affects expression | ISO | RGD:734269 | 6480464 | Acetaminophen affects the expression of ANXA5 mRNA | CTD | PMID:17562736 |
| paraquat | increases expression | EXP | | 6480464 | Paraquat results in increased expression of ANXA5 mRNA | CTD | PMID:20883675 |
| perfluorooctane-1-sulfonic acid | decreases expression | ISO | RGD:2120 | 6480464 | perfluorooctane sulfonic acid results in decreased expression of ANXA5 mRNA | CTD | PMID:18692542 |
| phenobarbital | multiple interactions | ISO | RGD:2120 | 6480464 | [Diethylnitrosamine co-treated with Phenobarbital] results in increased expression of ANXA5 protein | CTD | PMID:20935162 |
| phenytoin | multiple interactions | ISO | RGD:734269 | 6480464 | [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of ANXA5 mRNA | CTD | PMID:21224054 |
| pirinixic acid | increases expression | ISO | RGD:734269 | 6480464 | pirinixic acid results in increased expression of ANXA5 mRNA | CTD | PMID:20059764 PMID:18301758 |
| pirinixic acid | increases expression | ISO | RGD:734269 | 6480464 | pirinixic acid results in increased expression of ANXA5 mRNA | CTD | PMID:18301758 PMID:20059764 |
| pirinixic acid | multiple interactions | ISO | RGD:734269 | 6480464 | PPARA protein promotes the reaction [pirinixic acid results in increased expression of ANXA5 mRNA] | CTD | PMID:20059764 |
| pregnenolone 16alpha-carbonitrile | multiple interactions | ISO | RGD:734269 | 6480464 | Pregnenolone Carbonitrile inhibits the reaction [Lithocholic Acid results in increased expression of ANXA5 mRNA] | CTD | PMID:20359477 |
| quartz | increases expression | ISO | RGD:734269 | 6480464 | Quartz results in increased expression of ANXA5 protein | CTD | PMID:20085295 |
| quercetin | multiple interactions | EXP | | 6480464 | [Quercetin co-treated with TNFSF10 protein] results in increased expression of ANXA5 protein | CTD | PMID:18377872 |
| resveratrol | increases expression | EXP | | 6480464 | resveratrol results in increased expression of ANXA5 protein | CTD | PMID:12060119 |
| rifampicin | multiple interactions | ISO | RGD:734269 | 6480464 | [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of ANXA5 mRNA | CTD | PMID:21224054 |
| ruthenium atom | increases expression | EXP | | 6480464 | Ruthenium results in increased expression of ANXA5 protein | CTD | PMID:17210701 |
| sodium dichromate | increases expression | ISO | RGD:2120 | 6480464 | sodium bichromate results in increased expression of ANXA5 mRNA | CTD | PMID:22561333 |
| streptozocin | multiple interactions | ISO | RGD:2120 | 6480464 | Trientine inhibits the reaction [Streptozocin results in increased expression of ANXA5 protein] | CTD | PMID:21136691 |
| streptozocin | decreases expression | ISO | RGD:2120 | 6480464 | Streptozocin results in decreased expression of ANXA5 protein | CTD | PMID:19634143 |
| streptozocin | increases expression | ISO | RGD:2120 | 6480464 | Streptozocin results in increased expression of ANXA5 protein | CTD | PMID:21136691 |
| streptozocin | multiple interactions | ISO | RGD:2120 | 6480464 | Trientine inhibits the reaction [Streptozocin results in decreased expression of ANXA5 protein] | CTD | PMID:19634143 |
| trans-resveratrol | increases expression | EXP | | 6480464 | resveratrol results in increased expression of ANXA5 protein | CTD | PMID:12060119 |
| troglitazone | increases expression | EXP | | 6480464 | troglitazone results in increased expression of ANXA5 mRNA | CTD | PMID:19631733 |
| valproic acid | increases expression | ISO | RGD:734269 | 6480464 | Valproic Acid results in increased expression of ANXA5 mRNA | CTD | PMID:15345369 |
| valproic acid | increases expression | ISO | RGD:734269 | 6480464 | Valproic Acid results in increased expression of ANXA5 mRNA | CTD | PMID:19136453 PMID:15345369 |
| valproic acid | increases expression | ISO | RGD:734269 | 6480464 | Valproic Acid results in increased expression of ANXA5 mRNA | CTD | PMID:15345369 PMID:19136453 |
| vancomycin | decreases expression | ISO | RGD:734269 | 6480464 | Vancomycin results in decreased expression of ANXA5 mRNA | CTD | PMID:18930951 |
| vancomycin | increases expression | ISO | RGD:2120 | 6480464 | Vancomycin results in increased expression of ANXA5 mRNA | CTD | PMID:18289764 |
| zinc pyrithione | increases expression | EXP | | 6480464 | zinc pyrithione results in increased expression of ANXA5 mRNA | CTD | PMID:21424779 |